Exploiting tumor hypoxia for cancer treatment

Raymon Servatius Theodorus Niemans

Research output: ThesisDoctoral ThesisExternal prepared

1252 Downloads (Pure)


Hypoxia, i.e. low blood oxygen levels, is a common feature of solid tumours. Hypoxia causes tumour cells to become even more malignant. It is also associated with a poor prognosis and problems occurring during cancer treatment. This dissertation evaluates two potential cancer treatments targeting tumour hypoxia in a preclinical setting. We show that new substances targeting CA-IX, a protein occurring in hypoxic tumour regions, have promising anti-cancer effects. We also studied a new potential drug called CP-506. This substance is activated specifically in hypoxic regions. We demonstrate that CP-506 is a promising new substance with characteristics favourable for future clinical use. Our results confirm that treatment targeting tumour hypoxia is an interesting and promising approach to cancer.
Original languageEnglish
Awarding Institution
  • Maastricht University
  • Lambin, Philippe, Supervisor
  • Dubois, Ludwig, Co-Supervisor
  • Yaromina, Ala, Co-Supervisor
Award date26 Jun 2018
Place of PublicationMaastricht
Print ISBNs9789462339781
Publication statusPublished - 2018


  • cancer
  • tumour
  • hypoxia
  • CA-IX
  • CP-506
  • hypoxia-activated prodrug

Cite this